Protagonist Therapeutics Reports Q3 Earnings Beat with Significant Revenue Growth
Protagonist Therapeutics (PTGX) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a GAAP earnings per share (EPS) of $3.07, surpassing estimates by $0.38, while revenue reached $274.4 million, beating projections by $33.08 million. The massive year-over-year revenue surge of over 5,700% reflects a significant shift in the company's financial profile. Despite the earnings beat, shares saw a slight decline of 1.8% in after-hours trading, suggesting market volatility or high expectations surrounding the results.
Topics: biotechnology earnings beat revenue growth share repurchase